Immunic(NASDAQ) IMUX

Market Cap$190.29M

Since IPO (2019)-94%

5 Year-84%

1 Year+49%

1 Month-6%

$13.99

+0.00%

+0.00Today

After hours$14.03+$0.04 (+0.29%)

Immunic last closing stock price
Metric	Price	Date
Last close	USD 13.97	2026-07-31

Immunic stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+4.33%	USD 13.39	2026-07-24
1 month	-5.67%	USD 14.81	2026-07-01
3 month	+44.77%	USD 9.65	2026-05-01
Year to date	+161.76%	USD 5.34	2025-12-31
1 year	+48.6%	USD 9.40	2025-07-31
3 year	-40.04%	USD 23.30	2023-08-01
5 year	-84.18%	USD 88.30	2021-07-30
Since inception	-94.21%	USD 241.20	2019-04-15

Immunic Financials at a Glance

Market Cap

$190.29M

Revenue (TTM)

$0.00

Net Income (TTM)

-$104.29M

EPS (TTM)

-$6.03

P/E Ratio

-2.32

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$13.99

Volume

146,000.726

Open

$14.03

Price

$13.99

Volume

146,000.726

Open

$14.03

Previous Close

$13.97

Daily Range

$13.43 - $14.18

52-Week Range

$5.06 - $15.84

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$13.99

Volume

146,000.726

Open

$14.03

Previous Close

$13.97

Daily Range

$13.43 - $14.18

52-Week Range

$5.06 - $15.84

Estimated Earnings Date

Aug 6, 2026

IMUX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immunic

Immunic develops oral medicines for people with chronic immune system diseases. Its treatments aim to help those with conditions like multiple sclerosis and bowel disorders. The company focuses on making daily life easier for patients by targeting disease at its source.

Lab Coats and Capsules: Immunic’s Main Offerings

Vidofludimus calcium (IMU-838): Oral therapy in late-stage trials for multiple sclerosis and ulcerative colitis; 0% of revenue as of Q2 2025.
IMU-856: Oral drug in early trials to restore gut barrier function for bowel and immune-related diseases; 0% of revenue as of Q2 2025.
IMU-381: Preclinical oral therapy for gastrointestinal diseases; 0% of revenue as of Q2 2025.
Licensing agreements: Exclusive rights to develop new molecules for neuroinflammatory diseases; 0% of revenue as of Q2 2025.
Research programs: Ongoing work on treatments for neuroinflammatory, autoimmune, and viral diseases; 0% of revenue as of Q2 2025.

Growth Spurts and Strategic Moves

Secured exclusive rights to IMU-856 from Daiichi Sankyo in 2020.
Signed new licensing deal with Ludwig-Maximilians-University for neuroinflammatory molecules in 2025.
Completed patient enrollment for two Phase 3 trials of vidofludimus calcium in 2025.
Raised $5.1 million in April 2025 and $65 million in May 2025 through equity offerings.
Expanded research operations in Germany and Australia to support clinical programs.

What Makes Immunic Stand Out in the Crowd

Immunic specializes in oral drugs that target immune system disorders without suppressing the whole immune system. Its research teams in Germany and Australia help keep development costs lower. The company’s focus on restoring gut health and treating neurological diseases sets it apart from many competitors.

Five Things You Need to Know

No product revenue reported for Q2 2025, Q2 2024, or Q2 2023.
Net loss was $26.8 million in Q2 2025, up 25% from Q2 2024.
Cash and cash equivalents were $55.3 million as of June 30, 2025.
Operating expenses rose 19% year-over-year to $27.1 million in Q2 2025.
Company faces liquidity risks and possible Nasdaq delisting due to low share price.

Bottom Line

Immunic remains focused on developing new oral therapies for immune-related diseases. The company’s future depends on successful clinical trials and securing more funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Daniel Vitt, PhD

Website

imux.com

Headquarters

New York City, NY 10036, US

IMUX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-220.75%

Return on Capital

N/A

Return on Assets

-54.96%

Earnings Yield

-43.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$190.29M

Shares Outstanding

13.62M

Volume

146.00K

Avg. Volume

212.28K

Financials (TTM)

Gross Profit

-$33.00K

Operating Income

-$109.64M

EBITDA

-$104.13M

Operating Cash Flow

-$81.33M

Capital Expenditure

-$116.00K

Free Cash Flow

-$81.45M

Cash & ST Invst.

$186.63M

Total Debt

$421.00K

Immunic Performance Analysis

Immunic annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Immunic sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Immunic annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -37.84	-3.7%
2023	2023-12-31	USD -21.12	-44.2%
2024	2024-12-31	USD -10.03	-52.5%
2025	2025-12-31	USD -6.24	-37.8%

Immunic sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	20.0%
Q3	2025-09-30	35.0%
Q4	2025-12-31	-23.1%
Q1	2026-03-31	32.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$33.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$190.29M

N/A

Market Cap/Employee

$2.07M

N/A

Employees

N/A

Net Income

-$32.59M

-27.9%

EBITDA

-$32.56M

-28.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$186.63M

+1204.7%

Total Debt

$421.00K

-56.8%

Accounts Receivable

$354.00K

-43.9%

Inventory

$0.00

N/A

Long Term Debt

$146.00K

-30.5%

Short Term Debt

$275.00K

-64.1%

Return on Assets

-54.96%

N/A

Return on Invested Capital

-72.43%

N/A

Free Cash Flow

-$17.30M

+20.7%

Operating Cash Flow

-$17.30M

+20.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VXRTVaxart, Inc.

VXRTVaxart, Inc.$0.54+2.57%

RPTXRepare Therapeutics Inc.

RPTXRepare Therapeutics Inc.$2.65+0.00%

CBUSCibus, Inc.

CBUSCibus, Inc.$1.93+0.00%

ACETAdicet Bio, Inc.

ACETAdicet Bio, Inc.$9.11+0.55%

BMEABiomea Fusion, Inc.

BMEABiomea Fusion, Inc.$1.17-4.10%

ACRVAcrivon Therapeutics, Inc. Common Stock

ACRVAcrivon Therapeutics, Inc. Common Stock$1.50-1.32%

PMVPPMV Pharmaceuticals, Inc.

PMVPPMV Pharmaceuticals, Inc.$1.11-1.77%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About IMUX

What is the current price of Immunic?

Immunic is trading at $13.97 per share.

What is the 52-week range for Immunic?

Over the past 52 weeks, Immunic has traded between $5.06 and $15.84.

How much debt does Immunic have?

As of the most recent reporting period, Immunic reported total debt of $421.00K.

How much cash does Immunic have on hand?

Immunic reported $186.63M in cash and cash equivalents in its most recent financial results.

What is Immunic’s dividend yield?

Immunic does not currently have a dividend yield.

Immunic(NASDAQ) IMUX

Immunic Financials at a Glance

IMUX News

Immunic (IMUX) Q2 Loss Widens 25%

Why Immunic Plummeted by 21% on Thursday

Why Immunic Stock Is Soaring Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Immunic

Lab Coats and Capsules: Immunic’s Main Offerings

Growth Spurts and Strategic Moves

What Makes Immunic Stand Out in the Crowd

Five Things You Need to Know

Bottom Line

IMUX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Immunic Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IMUX

What is the current price of Immunic?

What is the 52-week range for Immunic?

How much debt does Immunic have?

How much cash does Immunic have on hand?

What is Immunic’s dividend yield?

Premium Investing Services